The involvement of PTX3 also in C3G is possible, because factor H-related protein 5 (FHR5), which is implicated in DDD and FHR5-related glomerulopathy, enhances complement activation by inhibiting binding of factor H to PTX3 (60). Here, CFHR5 is linked to glomerular disorder.